The Top 5 Biosimilar Articles From SABCS 2020

Here are the top 5 biosimilar articles from SABCS 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

The 2020 San Antonio Breast Cancer Symposium (SABCS) was held from December 8 to December 12, 2020. During the virtual conference, we covered study presentations that showed the potential for oncology biosimilars, particularly trastuzumab products, in the breast cancer space.

Here are the top 5 biosimilar articles from SABCS 2020.

Number 5: Studies of trastuzumab biosimilars have improved understanding of these medicines as monotherapy and in combination with other agents in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.

Number 4: Investigators explained the potential for durable antitumor efficacy of a novel trastuzumab biosimilar in patients with HER2-expressing or -driven tumors who have exhausted other treatment options.

Number 3: Investigators have reported pharmacokinetic findings that confirm the biosimilarity of Viatris’ trastuzumab biosimilar candidate (Ogivri) to reference Herceptin.

Number 2: A study of the trastuzumab biosimilar ABP 980 (Kanjinti) in Europe found strong uptake patterns, according to an abstract presentation.

Number 1: Investigators studying trastuzumab biosimilar savings and use rates across different disease settings in HER2-positive breast cancer observed dramatically increased usage of biosimilars and said payer policy appears to have contributed to higher biosimilar utilization.

To read all of these articles and more, visit